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Abstract Amyotrophic lateral sclerosis (ALS) is a pro-
gressive, fatal neurodegenerative disorder. Since no diag-
nostic laboratory test exists, the identification of specific
biomarkers could be fundamental in clinical practice.
microRNAs (miRNAs) are considered promising
biomarkers for neurodegenerative diseases. The aim of the
study was to identify a CSF miRNA set that could differ-
entiate ALS from non-ALS condition. miRNA profiling in
CSF from ALS patients (n = 24; eight with C9orf72
expansion) and unaffected control subjects (n = 24) by
quantitative reverse transcription PCR identified fourteen
deregulated miRNAs. Validation experiments confirmed
eight miRNAs as significantly deregulated in ALS. No
significant differences were observed between ALS
patients with or without C9orf72 expansion. The receiver
operator characteristic (ROC) curve analyses revealed the
highest diagnostic accuracy for the upregulated miR181a-
5p and the downregulated miR21-5p and miR15b-5p. The
miR181a-5p/miR21-5p and miR181a-5p/miR15b-5p ratios
detected ALS with 90 and 85 % sensitivity and 87 and
91 % specificity, respectively, confirming the application
potential as disease biomarkers. These deregulated miR-
NAs are implicated in apoptotic way and provide insight
into processes responsible for motor neuron degeneration.
Keywords Amyotrophic lateral sclerosis  Cerebrospinal
fluid  microRNA  C9orf72 expansion  Biomarkers
Introduction
Amyotrophic lateral sclerosis (ALS) is an untreatable, fatal
disease characterized by neurodegeneration involving pri-
marily motor neurons in the motor cortex, brain stem and
spinal cord. The selective loss of motor neurons causes the
progressive wasting and weakness of limb, bulbar and
respiratory muscles, paralysis and death, within 2–5 years
of symptom onset (Robberecht and Philips 2013).
Although most cases of ALS are reported as sporadic
(90 %), about 10 % of cases have a family history of ALS
(FALS) (Renton et al. 2014). Most commonly, familial
ALS presents with a Mendelian dominant mode of inher-
itance and high penetrance, although pedigrees with
incomplete penetrance or recessive inheritance have been
reported (Andersen and Al-Chalabi 2011). Currently, more
than twenty-five genes and several additional chromosomal
loci have been related to ALS, even though there is con-
sensus about the causal role only for a subset of major
genes as C9orf72, SOD1, TARDBP, and FUS (Marangi and
Traynor 2015). Among these, the massive hexanucleotide-
repeat expansion (GGGGCC)n, in the uncharacterized
C9orf72 gene, represents the most frequent genetic alter-
ation in FALS (23–47 %) and SALS (4–21 %) identified to
date (Millecamps et al. 2012).
Although the pathogenic mechanisms of neurodegener-
ation in ALS remain elusive, it is commonly accepted that
multiple interactions among genetic components, environ-
mental influences and epigenetic mechanisms contribute to
disease development. It was recently observed that epige-
netic mechanisms such as histone modifications, DNA
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methylation, RNA editing and posttranscriptional silencing
mechanisms contribute to the development and course of
ALS pathophysiology (Paez-Colasante et al. 2015). Mod-
ifications in RNA metabolism, including alterations in
microRNA (miRNA) biogenesis, spliceosome integrity and
RNA processing, are emerging as a novel common path-
way responsible for motor neuron degeneration. Several
apparently divergent biological effects can converge in this
pathway, leading to a disturbance in protein expression and
maturation, which contributes directly to motor neuron
death (Droppelmann et al. 2014). In particular, increasing
evidence underlines that miRNA deregulation is involved
in ALS pathogenesis (Maciotta et al. 2013; Goodall et al.
2013; Eitan and Hornstein 2016). miRNAs are short non-
coding RNA molecules (18–25 nucleotides) central to the
epigenetic process that play an important role as endoge-
nous regulators of gene expression. These small RNAs are
capable of controlling gene expression either by repression
of translation (Bartel 2009) or by mRNA degradation
(Wahid et al. 2010). The same miRNA may regulate
hundreds of target mRNAs and thus may affect complex
gene expression networks. miRNA expression patterns can
therefore be very informative. Moreover, miRNA mole-
cules are present in human body fluids in a remarkably
stable form (Mitchell et al. 2008; Gallego et al. 2012).
Recent evidence indicates that these miRNAs can reveal
changes in the cells of origin, including neurons. In the
case of CNS disorders, miRNAs detected in CSF can
reflect brain physiological and pathological conditions and
represent a more sensitive marker of changes than those
present in blood or other body fluids (Rao et al. 2013;
Roberts et al. 2015). For these reasons, in the last few
years, miRNAs have aroused great interest as potential
biomarkers in neurological disorders. Expression levels of
miRNAs in CSF have been investigated in Multiple
Sclerosis (MS) (Haghikia et al. 2012), Alzheimer’s Disease
(AD) (Cogswell et al. 2008; Mu¨ller et al. 2014; Burgos
et al. 2014; Denk et al. 2015) and Parkinson’s Disease (PD)
(Burgos et al. 2014), with promising results. Specific
biomarkers for ALS have not been identified yet, and the
diagnosis of ALS is mostly based on electrophysiological
examinations and clinical assessment with a history of
symptom progression, with a considerable delay from
symptom onset. The identification of specific biomarkers
would allow an earlier and accurate diagnosis of ALS, with
the opportunity to start an earlier treatment able to alter the
disease course. Moreover, the finding of a deregulated
miRNA expression in patients with ALS could provide
important insights about the pathogenesis of the disease
and eventually contribute to the development of potential
future therapies.
To date, only two reports have been published on
miRNAs in CSF from ALS patients using different
approaches. In the first study, CSF samples from 22 ALS
patients and 24 healthy controls were screened for a
specific set of miRNAs binding TDP-43 (Freischmidt et al.
2013), identifying a subset of 5 deregulated miRNAs. In
the second study, carried out on 10 ALS patients and 10
unaffected controls, the authors investigated the expression
of one selected miRNA, previously found over-expressed
in ALS blood leucocytes (De Felice et al. 2012, 2014). In
the present study, we have performed the profiling of the
miRNA population in CSF from ALS patients and unaf-
fected control subjects, to identify a pattern of miRNAs
that is specifically deregulated, and able to discriminate
ALS from non-ALS. We profiled the expression of a panel
of most abundantly expressed and best-characterized
miRNAs by quantitative real-time PCR (qRT-PCR), a
well-established method, which represents a highly sensi-
tive and specific mean for the evaluation of miRNA
profiles.
Materials and Methods
Patient Data and CSF Samples
CSF samples from 24 sporadic ALS patients were avail-
able for the present study. ALS diagnosis was performed
according to World Federation of Neurology El Escorial
Revised criteria, and patients with no evidence of a
family history of the disease were classified as sporadic
(Brooks et al. 2000). All patients were previously
screened for mutations in the major genes associated with
the disease.
Among the 24 patients included in the study, 8 were
positive for C9orf72 expansion. The unaffected control
group consisted of 24 age- and sex-matched subjects who
underwent lumbar puncture for neurological or microbio-
logical diagnostic purposes and were negative for all the
performed tests. Characteristics of ALS patients and con-
trols are summarized in Table 1.
The CSF, free of blood contamination, was centrifuged
(16009g, 4 C, 15 min), frozen within 40 min of collec-
tion and stored at -80 C until use. All procedures from
withdrawal to storage of CSF samples were performed
according to the Guidelines for CSF Biobanking for Bio-
marker Research (Teunissen et al. 2014).
miRNA profiling was performed in a total of six pooled
CSF samples (total volume 200 ll), consisting of three
pools derived from ALS patients and three pools from
control subjects. Each pool was composed of an equal
volume (25 ll) of four CSF samples from females and four
CSF samples from males. miRNA validation experiments
were carried out starting with 200 ll of CSF from each
individual.
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Written consent was obtained from each participant.
This study was approved by the local ethics committee in
accordance with the ethical standards of the Declaration of
Helsinki and was carried out according to the international
Good Laboratory Practice (GLP) and Good Clinical Prac-
tice (GCP) standards.
RNA Extraction and Reverse Transcription
Total RNA was extracted employing the miRNeasy Mini
kit (Qiagen, Hilden, Germany). Synthetic exogenous Ce-
miR-39 (Cel-miR-39-3p) from Cenorabditis Elegans was
added into each sample according to the manufacturer’s
recommendations. Purified RNA was stored at -80 C in
RNase-free water. Standard procedures were employed to
ensure the quality and the reproducibility of the pre-ana-
lytical step.
Isolated RNA was used as starting material for reverse
transcription (RT) employing the miScript II RT kit (Qia-
gen) that provides the polyadenylation of mature miRNAs
and reverse transcription into cDNA using oligo-dT pri-
mers. In order to manage the quality of performed proce-
dures, we used miScript miRNA QC PCR Array (Qiagen)
that ensures the selection of only high-quality samples,
employable in subsequent experiments, by testing the
quality of RNA isolation and cDNA preparation.
miRNA Profiling by qPCR
cDNA prepared by RT reaction from RNA of pools was
utilized as the template for real-time quantitative PCR
(qPCR) analysis, performed in the 7900HT Fast Real-Time
PCR System (Thermo Fisher Scientific, Waltham, MA,
USA) using the human-miFinder 384HC miRNA PCR
array (Qiagen), which profiles the expression of 372 most
abundantly expressed and best-characterized miRNAs in
miRBase (www.mirbase.org). According to the manufac-
turer’s recommendations, a final volume of 10 ll con-
taining cDNA properly diluted and SYBR Green-based
real-time PCR (Qiagen) was dispensed on human-miFinder
PCR array.
Relative expression quantification was performed by the
comparative cycle threshold (Ct) method (2
DDCt ). Thus,
the first step of qPCR analysis consisted of reference
miRNA selection for normalization of miRNA expression.
The miRNA608 and miR328-3p were selected by
RefFinder free software (Xie et al. 2012) from a panel of
eight potential endogenous reference miRNAs, since their
expression showed high stability and reproducibility across
different samples and experiments. The miR-39-3p of
Caenorhabditis elegans (Cel-miR-39-3p) was also
employed as exogenous control for the normalization. The
control group was used as the calibrator in the calculation
of fold change. miRNAs with a fold change B-1.5 were
considered downregulated and miRNAs with a fold change
C1.5 were considered upregulated.
Free software miScript miRNA PCR Array Data Anal-
ysis (Qiagen), available at http://pcrdataanalysis.sabios
ciences.com/mirna, was employed for the analysis of qPCR
results of miRNA profiling experiments. Only miRNAs
with Ct\35 and with a high efficiency amplification plot
were taken into consideration for subsequent analysis. The
ALS patients and control groups were compared using
Student t test, and the cut off for the p value was set at 0.05.
miRNA Validation
Validation experiments of miRNAs selected in the profil-
ing were performed in triplicate by SYBR Green-based
real-time PCR analysing individually CSF sample obtained
from each subject. The Cel-miR-39-3p and both endoge-
nous miR608 and miR328-3p were used in the validation
experiments as reference miRNAs to normalize miRNA
expression values. Relative quantification was carried out
using Data Assist v3.0 (Thermo Fisher Scientific). miRNAs
were considered downregulated for fold change values
B-1.5 and upregulated for values C1.5. Similarly to the
miRNA profiling, the miRNA molecules with Ct[35 were
excluded from subsequent data analyses.
Statistical Analysis for miRNA Validation
All statistical analyses were performed with SPSS (Version
18; SPSS Inc, Chicago, IL, USA) and GraphPad Prism
(Version 5.0; GraphPad Software Inc, San Diego, CA,
USA). Normality of data was assessed by the Shapiro–
Table 1 Characteristics of ALS
patients and controls
Patients w/o mutation C9orf72 patients Control subjects
No of subjects 16 8 24
Gender 8M/8F 4M/4F 12M/12F
Age mean ± SD (years) 63.94 ± 8.45 60.50 ± 8.50 58.25 ± 5.04
Age at onset 59.0 ± 14.4 57.55 ± 12.6
Bulbar onset 25.0 % 25.0 %
Disease duration (months) 41.5 ± 20.5 47.0 ± 19.7
Neuromol Med
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Wilk test. Statistical differences were verified by Student’s
unpaired two-tailed t test in the case of normal distribu-
tions, or two-tailed Mann–Whitney U test in the case of
non-normal distributions. Analysis was performed for
every miRNA, and ratios between different miRNAs were
examined to identify any specific characteristics in ALS.
The ratio between miRNAs was calculated as 2DCt
(DCt = Ct of upregulated miRNA - Ct of downregulated
miRNA), as described by Sheinerman et al. (2012).
Receiver operating characteristic (ROC) curves were
plotted to evaluate the power of miRNAs (singles or in
combination) to differentiate ALS patients from controls.
Differences among groups of patients, stratified based
on C9orf72 expansion and clinical features (age, gender,
site of onset, disease duration) were evaluated by Student’s
unpaired two-tailed t test or two-tailed Mann–Whitney
U test in the case of normal distributions or non-normal
distributions, respectively. Spearman’s rho (r) was calcu-
lated to find correlation between miRNA expression level
and age at onset. Association of each single miRNA
expression level with disease duration was estimated using
the Kaplan–Meier method and compared by the log-rank.
Analysis was performed considering only deceased patients
and considering both living and deceased individuals, using
a censored approach. Patients were divided into high
miRNA expression group (miRNA levels greater than the
median) or low miRNA expression group (miRNA levels
less than the median). p values smaller than 0.05 were
considered statistically significant.
Results
miRNA Profiling and Identification of Differentially
Expressed miRNAs
The CSF profiling permitted the amplification by real-time
PCR of 35 (9.4 %) and 39 (10.4 %) miRNAs in CSF pools
from ALS patients and control subjects, respectively, for a
total of 42 out of 372 (11 %) miRNAs positively detected
in our sample cohort. No detectable traces or traces with
Ct[ 35 were identified for 330 miRNA molecules. Fur-
thermore, our results showed an overall downregulation of
miRNAs in CSF from ALS patients compared to controls;
indeed, the majority of deregulated miRNAs were
downregulated.
From miRNA profiling analysis, we selected thirteen
downregulated miRNAs (let7a-5p, let7b-5p, let7f-5p,
miR15b-5p, miR21-5p, miR122-3p, miR127-3p, miR148a-
3p, miR150-5p, miR183-3p, miR195a-5p, miR204-5p,
miR373-5p) and one upregulated miRNA (miR181a-5p).
Among these deregulated miRNAs, three (let7-a, miR195a-
5p and miR21-5p) were significantly downregulated with a
p value of 0.0023, 0.039 and 0.030, respectively. The
changes in the other eleven miRNAs did not reach statis-
tical significance even though they were downregulated
with a fold change C1.5. The results of miRNA profiling
were graphed in the Volcano Plot reported in Fig. 1.
Expression profiles of selected CSF miRNAs
The fourteen deregulated miRNAs were validated in CSF
samples obtained from each subject by qPCR. The dereg-
ulation observed in the profiling was confirmed, with an
overall miRNA downregulation and only miR181a-5p
upregulated. Among the fourteen selected molecules, eight
Fig. 1 Volcano Plot of log2 of the fold change for each miRNA and
its p value. The p value is calculated based on the Student’s t test of
the replicate 2DCt values for each miRNA in the control group and
patient group. The central vertical line in the graph indicates a fold
change of 1. Vertical sliders indicate miRNAs as either up or down
regulated with a fold change[ 1.5. The spots beyond right vertical
slider indicate the upregulated miRNA, and the spots beyond the left
slider indicate the downregulated miRNAs. The horizontal line,
parallel to the x axis, indicates the desired threshold for the p value of
the Student’s t test, defined\0.05. The Volcano Plot was generated
by the software miScript miRNA PCR Array Data Analysis (Qiagen)
Neuromol Med
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miRNAs were significantly deregulated in ALS patients
compared to controls (Fig. 2). In particular, changes in
miR21-5p, miR195-5p and let7a-5p, which were signifi-
cantly downregulated in miRNA profiling, were confirmed
in the validation experiments, and a significant downreg-
ulation was also reported for miR148-3p, miR15b-5p,
let7b-5p and let7f-5p. The miRNA181a-5p was confirmed
as upregulated in CSF from ALS patients. No significant
difference was evidenced for the other six miRNAs
included in the validation experiments.
The levels of the eight deregulated miRNAs were
analysed in the ALS patient group to evaluate possible
correlations with C9orf72 expansion and clinical variables.
The C9orf72 repeat expansion, which represents the most
frequent genetic alteration in ALS, was present in 8 out of
the 24 patients included in the study. No significant dif-
ferences in miRNA expression levels were observed
between ALS patients with or without the expansion.
Association of miRNA levels with gender, site of disease
onset (spinal versus bulbar) and age at disease onset was
also evaluated. No significant associations were found with
the ALS clinical variables examined. The results are
summarized in Table 2. Survival analysis did not reveal
any association with the disease duration, using a censored
approach, and considering only deceased individuals (data
not shown). A shorter disease duration was correlated with
Fig. 2 Scatter graphs of results
of CSF validation experiments
for the eight significantly
deregulated miRNAs. p values
were calculated using two-tailed
Mann–Whitney U test. Relative
expression of deregulated
miRNAs in CSF from ALS
patients and controls normalized
by 2DCt is graphed (log10 scale
on the y axis), and medians are
indicated as horizontal lines.
ALS Amyotrophic Lateral
Sclerosis patients, CTR control
subjects
Neuromol Med
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the contemporary presence of low miR15b-5p and miR21-
5p expression levels and high miR181a-5p expression,
even though the correlation was not statistically significant
(p = 0.064).
The receiver operator characteristic (ROC) curve anal-
yses revealed that all the eight significant miRNAs could
be potential biomarkers for ALS diagnosis. However,
among these miRNAs, the upregulated miR181a-5p and
the downregulated miR21-5p and miR15b-5p showed the
highest diagnostic accuracy (Fig. 3). The miR181a-5p
levels gave an area under the ROC curve (AUC) of 0.815
(95 % CI 0.677–0.953). At the cutoff value of 6.16, the
optimal sensitivity and specificity were 87 and 70 %,
respectively. The downregulated miR21-5p and miR15b-
5p gave areas under the ROC of 0.878 (95 % CI
0.761–0.996) and 0.87 (95 % CI 0.757–0.982), respec-
tively. At the cutoff value of 4.01 for miR21-5p, the
optimal sensitivity and specificity were 95 and 74 %,
respectively, and at the cutoff value of 8.17 for miR15b-5p
the optimal sensitivity and specificity were 95 and 74 %,
respectively.
The three miRNAs with the highest diagnostic accuracy,
revealed by ROC curve, were analysed in combination.
Values obtained from ratios between the upregulated
miRNA and the two-downregulated miRNAs were exam-
ined comparing patients and controls. A significant
deregulation was reported for the analyses of both
miR181a-5p/miR21-5p (p\ 0.0001) and miR181a-5p/
miR15b-5p (p\ 0.0001). The ROC curve analysis of
miR181a-5p/miR21-5p ratio showed an area under the
curve of 0.917 (95 % CI 0.836–0.999). At the cutoff value
of 0.45, the optimal sensitivity and specificity were 90 and
87 %, respectively. The miR181a-5p/miR15b-5p ratio gave
an area under the ROC of 0.922 (95 % CI 0.844–0.996).
The optimal sensitivity and specificity were 85 and 91 %
respectively, at the cutoff value of 29.8 (Fig. 3).
Discussion
This paper provides the first description of CSF miRNA
profiling in ALS identifying a pattern of miRNAs specifi-
cally deregulated to use as biomarkers for ALS. The
miRNA profiling, defined as the measurement of the rela-
tive abundance of a cohort of miRNAs detectable in cell-
free (Pritchard et al. 2012), is the more promising approach
for identification of miRNA biomarkers. We profiled the
expression of a panel of 372 miRNAs representing the
most abundantly expressed and best-characterized miRNAs
in miRNA-databases. A total of 48 CSF samples (24 from
sporadic ALS patients and 24 controls) were analysed
applying qRT-PCR in two phases: initial screening by
miRNA-array and subsequent validation of selected
molecules. Among the various techniques for miRNA
profiling, we chose the quantitative reverse transcription
PCR (qRT-PCR) since it is the most specific and sensitive
established (Pritchard et al. 2012). This technique provides
the immediate availability of quantitative data using
nanograms of RNA and gives the possibility to study a
consistent number of specific miRNAs with well-known
mRNA targets and molecular functions (Pritchard et al.
2012; Pacifici et al. 2014). As in several miRNA profiling
studies, the initial screening was performed in pooled
samples. This approach, using a sensitive assay such as
qRT-PCR, offers a competitive and cost-effective tool for
identification of ALS miRNAs.
The profiling allowed the detection of 42 out of 372
miRNAs. The percentage of miRNAs detected in our study
(11 %) was congruent with that recently reported by Denk
et al. (2015) (15 %) who used qRT-PCR to profile 384
different miRNAs in CSF from AD patients.
A total of fourteen deregulated miRNAs was selected
from the profiling: thirteen that were downregulated
(let7a-5p, let7b-5p, let7f-5p, miR15b-5p, miR21-5p,
Table 2 Correlations between
miRNAs level and C9orf72
expansion, and ALS clinical
variables
miRNA C9orf72* Disease duration (censored) Site of onset Gender Age at onset
let7a-5p 0.750 0.240 0.266 0.436 0.769
let7b-5p 0.750 0.379 0.267 0.631 0.384
let7f-5p 0.750 0.253 0.349 0.971 0.658
miR15b-5p 1.000 0.070 0.497 0.684 0.270
miR21-5p 0.437 0.515 0.197 0.481 0.156
miR148a-3p 0.617 0.242 0.230 0.052 0.076
miR181a-5p 1.000 0.542 0.933 0.393 0.137
miR195-5p 0.211 0.745 0.211 0.796 0.286
* Patients were dichotomized in carriers and non-carriers of the C9orf72 expansion
For each column p values are reported
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miR122-3p, miR127-3p, miR148a-3p, miR150-5p,
miR183-3p, miR195a-5p, miR204-5p, miR373-5p) and one
upregulated (miR181a-5p). We observed an overall
downregulation of miRNAs in ALS samples, consistent
with other studies reporting that the majority of deregulated
miRNAs in tissues from ALS patients and ALS models are
downregulated (Paez-Colasante et al. 2015).
In order to confirm these results, the expression levels of
selected miRNAs were analysed in each single sample
included in the pool, using qRT-PCR. A group of 8 out of
the 12 miRNAs selected by miRNA profiling were con-
firmed as significantly deregulated: seven were downreg-
ulated (let7a-5p, let7b-5p, let7f-5p, miR15b-5p, miR21-5p,
miR148a-3p, miR195a-5p) and one upregulated (miR181a-
5p). We observed an interesting overlapping of six dereg-
ulated miRNAs in our dataset (miR181a-5p, miR21-5p,
miR148a-3p and let7a-5p, let7b-5p and let7f-5p) with those
described by Burgos et al. (2013), who listed the 50 most
abundant miRNAs detectable in CSF. This observation
suggests that the majority of miRNAs selected in this study
should be specific for nervous tissue and have a brain
origin.
The selected miRNAs have not been identified as sig-
nificantly deregulated in the two previously published
studies (Freischmidt et al. 2013; De Felice et al. 2014). A
possible explanation for this discrepancy could be the
different strategies used to identify the deregulated miR-
NAs: the use of a set of TDP-43 binding miRNAs (Freis-
chmidt et al. 2013), or the analysis of one selected miRNA,
found over-expressed in ALS blood leucocytes (De Felice
et al. 2014). Only for let7b-5p is there a partial overlapping
with Freischmidt and colleagues’ study, which reported a
decrease of let7b in CSF from ALS patients, even though it
did not reach statistical significance (Freischmidt et al.
2013).
Regarding other neurodegenerative diseases, two studies
reported a significant downregulation in expression levels
of both miR15b-5p and miR181a-5p in CSF from AD
Fig. 3 Receiver operating characteristic (ROC) curve for the upreg-
ulated miRNA (miR181a-5p) and the two-downregulated miRNAs
(miR15b-5p and miR21-5p), which showed the highest significant
differences in validation phase for discriminating ALS patients from
controls. For miR181a-5p, the normalized expression level (2DDCt )
was selected as test variable and for the miR21-5p and miR15b-5p the
logarithm of the normalized expression level. In the case of analyses
in combination, ROC curve was obtained for the ratios between
miRNAs, calculated as 2DCt (DCt = Ct miR181a-5p - Ct miR21-5p
and Ct miR181a-5p - Ct miR15b-5p). AUC (area under the ROC
curve), sensitivity and specificity are reported for each ROC curve
Neuromol Med
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patients (Cogswell et al. 2008; Burgos et al. 2014). Thus, in
CSF from ALS patients, the levels of miR15b-5p seem to
follow the same trend described in AD patients, whereas
the deregulation of miR181a-5p shows an opposite
tendency.
Among the significantly deregulated miRNAs,
miR181a-5p, miR15b-5p and miR21-5p showed the high-
est sensitivity and specificity in differentiating ALS from
age-matched controls. Moreover, sensitivity and specificity
of these miRNAs were increased when they were paired
combining the upregulated miRNA with the downregulated
miRNAs (miR181a-5p/miR15b-5p and miR181a-5p/
miR21-5p). Thus, miR15b-5p, miR21-5p and miR181a-5p
might be strong candidates for new ALS biomarkers.
Furthermore, the observation that miR181a-5p was down-
regulated in CSF from AD patients increased the applica-
tion potential of this miRNA as specific marker of ALS.
In the present study, no associations were found between
miRNA levels and ALS clinical variables. This result can
be affected by the relatively limited number of patients
included in each group. It is worth noting that in the case of
survival analysis, the contemporary presence of low
miR15b-5p and miR21-5p levels and high miR181a-5p
levels was related to a shorter disease duration, even
though it did not reach the statistical significance. Further
analyses in a larger cohort of ALS patients will allow
confirming or ruling out the possible association of these
three deregulated miRNAs with the disease duration.
Moreover, no significant differences were present when
miRNA levels of patients carrying the C9orf72 expansion
were compared with those of patients without the expan-
sion. Although the analysis was performed in a relatively
small number of patients, these data suggest a possible
mutation-independent deregulation of CSF miRNAs. This
is in line with the results obtained in a recent study of
miRNA in the serum of sporadic ALS patients, in which
deregulated miRNAs revealed the same trend in patients
with or without mutations in the major ALS genes,
including C9orf72 expansion (Freischmidt et al. 2014).
Although a subsequent study performed by the same
research group reported a higher heterogeneity in serum
miRNA pattern in sporadic ALS patients, the authors
confirmed that more than 60 % of sporadic ALS samples
shared a serum miRNA fingerprint with genetic cases
(Freischmidt et al. 2015). It is hypothesized the presence of
common pathogenic denominators, possibly related to a
polygenetic background, conferring susceptibility for ALS
and connecting defects in the majority of sporadic ALS and
in ALS associated with mutation in different genes
(Freischmidt et al. 2015).
The present study has some limitations and strengths.
First, the approach used to identify deregulated miRNAs
can affect the results. We have employed qRT-PCR which
is a highly sensitive technique, but cannot identify novel
miRNAs. Thus, it is possible that other informative miR-
NAs exist in CSF. On the other hand, validation experi-
ments showed that this method is not only sensitive and
specific but also reproducible and accurate to detect miR-
NAs in CSF. In addition, all the steps of the qRT-PCR have
been monitored by quality control procedures, to ensure the
reliability of the results. A second challenge in miRNA
quantification is data normalization that is a key point for
an objective evaluation of expression levels. For miRNA
analysis in CSF, no consensus internal controls have been
established yet. We used two endogenous reference miR-
NAs (miRNA608 and miR328-3p), selected as the most
stable and reproducible across different samples and
experiments, and an exogenous control (Cel-miR-39-3p),
widely reported in the literature. The analyses performed
using the three reference miRNAs led to the same results.
Regarding the individuals enrolled in the study, a strength
is that all patients were clinically and genetically charac-
terized and followed up and control subjects were matched
to cases so as to eliminate the potential confounding effects
of age and gender. A limitation is the relatively small
number of patients enrolled in the study. The experiments
reported here demonstrate that differentially expressed
miRNAs in CSF represent informative markers able to
distinguish ALS patients from unaffected control subjects;
however, the results have to be confirmed in a larger cohort
of patients. In addition, replication studies will allow to
increase the number of ALS patients and to stratify them
based on clinical and genetic features, to better evaluate the
potential associations of miRNAs with these variables.
Finally, in this study CSF miRNA levels of ALS patients
have been compared to those of control subjects not
affected by neurological disorders. It will be of funda-
mental importance to extend the comparison to patients
affected by other neurodegenerative diseases, to evaluate
the specificity of deregulated miRNAs as ALS biomarkers.
Besides their role as potential biomarkers, the deregu-
lated miRNAs could reflect the biology of the tissue of
origin, providing important insight into disease processes
responsible for motor neuron degeneration. The majority of
miRNAs analysed in this study are molecules with well-
known functions, and the information about their potential
role derives mainly from studies of brain tumours. Abun-
dant data have recently shown a very tight connection
between miR21 and miR15, and the use of these two
miRNA in combination has been proposed as specific
signature for glioma (Baraniskin et al. 2012). Further
studies reported a significant upregulation of miR21
expression levels in CSF from patients with glioblastoma
(Akers et al. 2013, 2015), supporting the hypothesis that
miR21 could be a marker of glial cell proliferation (Garg
et al. 2015). Finally, miR181a-5p has been reported as
Neuromol Med
123
downregulated in neuroblastoma, glioblastoma and glioma
(Conti et al. 2009; Shi et al. 2008; Gibert et al. 2014). It is
worth noting that in brain tumours, the deregulation of
these three miRNAs displays a trend opposite of that
observed in ALS in our study, where miR181a-5p is
upregulated and miR21-5p and miR15b-5p are downregu-
lated. It has been proposed that in the glioma, glioblastoma
and astrocytoma carcinogenesis, these three miRNAs may
act in combination as promoters of glial cell proliferation
(Shi et al. 2008; Conti et al. 2009; Teplyuk et al. 2012). In
particular, miR21-5p and miR-15b have been described as
oncomirs, since they work as oncogenes and their over-
expression leads to tumour growth, inhibiting the expres-
sion of tumour suppressor genes (Papagiannakopoulos
et al. 2008; Pang et al. 2015). The miR181a-5p has been
suggested as an anti-oncomir, which acts as a tumour
suppressor in normal tissues, that triggers growth inhibi-
tion, apoptosis, and inhibits invasion (Conti et al. 2009). In
the light of this evidence, it can be hypothesized that,
whereas the contemporary downregulation of miR181a-5p
and upregulation of miR21-5p and miR15b-5p are associ-
ated with apoptotic mechanism inhibition and cell prolif-
eration, the contemporary upregulation of miR181a-5p and
downregulation of miR21-5p and miR15b-5p we find could
be linked to cell death by favouring apoptotic pathways.
This deregulation could directly involve microglia, which
in turn may contribute to neuronal damage. Functional
in vitro studies will allow verifying though these deregu-
lated miRNAs are related to apoptotic mechanisms
responsible for cell death in ALS.
In summary, considering the high diagnostic value of
combined miR181a-5p, miR15b-5p and miR21-5p analyses
in this pilot study, we provide initial evidence that identi-
fied miRNAs could represent promising biomarkers for
ALS. If replicated in a larger cohort of patients, these
molecules may provide a valuable diagnostic tool. In per-
spective, these miRNAs may be used as prognostic
biomarkers and as indicator of disease progression, to
facilitate clinical management of this disease. Moreover,
besides of the potential role of miRNAs as biomarkers, the
finding of a deregulated miRNA expression in patients with
ALS may provide important insights about the pathogen-
esis of the disease and eventually contribute to develop
potential future therapeutic approaches.
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